Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015841
Chunk: 10

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 10
---
 contained on our website is not incorporated by reference into this prospectus, and you should not consider information contained on our website to be part of this prospectus or in deciding whether to purchase our securities.

Recent Developments

Antev Acquisition

On April 26, 2025, the Company signed a binding letter of intent to acquire Antev, a UK-based late clinical-stage drug development company. On June 29, 2025, the Company, Antev and the Antev Vendors entered into the Definitive Agreement pursuant to which the Company agreed to acquire all of the issued and outstanding shares of Antev, on a fully diluted basis, in exchange for up to 2,666,600 of the Company's common shares or certain cash consideration pursuant to a "tag offer". In addition to resale restrictions prescribed under applicable securities law, common shares issued to Antev Vendors will be subject to a staggered lock-up and an agreement granting certain voting rights in favor of management of the Company for 36 months. Upon the achievement of certain milestones related to potential future FDA Phase 2 and New Drug Administration approvals, as more particularly described in the Definitive Agreement, the Antev Vendors will be entitled to receive up to approximately $65 million in additional contingent consideration. This prospectus is part of the registration statement filed on Form S-1 pursuant to the Definitive Agreement to register for resale by the Selling Shareholders of certain of the Consideration Shares from time to time. The foregoing description of the Definitive Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Definitive Agreement, which is filed as Exhibit 2.4 hereto and is incorporated herein by reference.

The Antev Transaction was completed on August 29, 2025, with the Company acquiring 98.6% of the Antev shares for aggregate consideration consisting of approximately $2.97 million in cash and 1,603,164 common shares of the Company. Pursuant to the Antev Transaction, the Company is now developing Teverelix, a next generation GnRH antagonist, a potentially first in market product for high-risk prostate cancer patients and patients with first AUR episodes due to enlarged prostate. Teverelix is a long-acting GnRH antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with